Aflac Incorporated (AFL) is a supplemental health and life insurance company operating two main segments, Aflac Japan and Aflac U.S. Its stock price has run ahead of the average analyst price target, which creates an unusual setup for a "Can AFL reach..." analysis.
Across the 15 to 16 analysts tracked by S&P Global and MarketBeat, the arithmetic mean of individual price targets is roughly $117, a figure that is below the latest close of $123.89. That mean fails the requirement that a meaningful target sit at least 10% above the market price. The targets above the current price—roughly $133 at Bank of America, $125 at Morgan Stanley, and $138 at Piper Sandler—also do not average out to a level 10% or more above the current quote.
As a result, the central target here comes from public discussion rather than an aggregate: Piper Sandler's $138 price target, the highest current target on the Street and one attached to an Overweight (buy-equivalent) rating. For context, the full analyst range is roughly $99 to $138, with cautious firms such as Barclays and Wolfe Research near the low end. The $138 figure represents a bullish case, not a consensus view.
With shares near $123.89, reaching $138 implies an upside of about 11%—a modest double-digit move that would take the stock to a fresh 52-week high above its prior peak near $130.22.
The stock trades at a trailing P/E (price-to-earnings ratio) in the low-to-mid teens and offers a dividend yield near 2%, positioning it as a defensive, income-oriented financial. A path toward $138 would likely require a combination of renewed earnings momentum, stabilization in the yen, and a broader rotation toward insurance carriers rather than a re-rating to a much higher valuation multiple on its own.
Aflac shares sit above both the 50-day moving average near $116.72 and the 200-day moving average near $115.87, indicating a constructive longer-term trend. The key resistance level is the 52-week high near $130.22, with $130 acting as a psychological round-number barrier. The $138 target would require a clean breakout above that prior high. On the downside, the $116–$117 zone and the 52-week low near $105.48 are notable support levels.
Analyst price targets typically reflect a roughly 12-month research horizon, though the specific horizon for each firm is not always disclosed. The next major catalyst is Aflac's third-quarter 2026 earnings, scheduled for release on November 4, 2026, after the market close, with a conference call the following day. Consensus calls for EPS of about $1.80 on revenue near $4.12 billion. Investors should also watch yen/dollar moves, U.S. benefit ratios, guidance, and any further analyst target revisions, which have been frequent in recent months.
AI Daily Buy/Sell Signals uses artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For a name like Aflac, where the stock trades above the average analyst target and technical levels matter, such tools can help traders discover opportunities, monitor positions, and spot shifting trends more efficiently than manual review. Exploring AI-generated signals alongside fundamental research can add a useful second perspective for active market participants.
Whether Aflac (AFL) can reach $138 depends on resolving a clear tension: a durable, dividend-growing franchise trading above the average analyst price target, against a Street consensus that is mostly Hold-rated with targets below the current price. The $138 figure is the most bullish current target on the Street, requiring about an 11% move to a new 52-week high. Support could come from Japan's margin gains and steady capital returns, while a weak yen, U.S. margin pressure, and soft earnings expectations are the principal obstacles. With third-quarter results imminent, guidance and currency trends are the next items to watch. The path to $138 is plausible only under a constructive earnings and currency scenario, and no outcome is guaranteed.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, AFL has been loosely correlated with CNO. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if AFL jumps, then CNO could also see price increases.